Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies

被引：8

作者：

Castillo, Jorge J. ^{[1
]}

Iyengar, Meera ^{[2
]}

Kuritzky, Benjamin ^{[2
]}

Bishop, Kenneth D. ^{[2
]}

机构：

[1] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA

[2] Rhode Isl Hosp, Div Hematol & Oncol, Providence, RI USA

来源：

ONCOTARGETS AND THERAPY | 2014年 / 7卷

关键词：

phosphatidylinositol-3-kinase pathway; inhibitors; leukemia; lymphoma; myeloma; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMA; 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; P110-DELTA ISOFORM; 3-KINASE; CAL-101; MTOR; NVP-BEZ235; PI3K;

D O I：

10.2147/OTT.S34641

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In the last decade, the advent of biological targeted therapies has revolutionized the management of several types of cancer, especially in the realm of hematologic malignancies. One of these pathways, and the center of this review, is the phosphatidylinositol-3-kinase (PI3K) pathway. The PI3K pathway seems to play an important role in the pathogenesis and survival advantage in hematologic malignancies, such as leukemia, lymphoma, and myeloma. The objectives of the present review, hence, are to describe the current knowledge on the PI3K pathway and its isoforms, and to summarize preclinical and clinical studies using PI3K inhibitors, focusing on the advances made in hematologic malignancies.

引用

页码：333 / 342

页数：10

共 54 条

[1] Computed Tomography Screening for Lung Cancer: Has It Finally Arrived? Implications of the National Lung Screening Trial [J].

Aberle, Denise R. ;

Abtin, Fereidoun ;

Brown, Kathleen .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :1002-1008

[2] The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro [J].

Amrein, Lilian ;

Shawi, May ;

Grenier, Jeremy ;

Aloyz, Raquel ;

Panasci, Lawrence .

INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (01) :247-252

[3]

[Anonymous], ASCO M

[4]

[Anonymous], ASCO M

[5]

Barrientos JC, 2013, ASCO M ABSTR S, V31, P7017

[6] Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma [J].

Baumann, Philipp ;

Schneider, Laura ;

Mandl-Weber, Sonja ;

Oduncu, Fuat ;

Schmidmaier, Ralf .

ANTI-CANCER DRUGS, 2012, 23 (01) :131-138

[7] The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma [J].

Bhende, P. M. ;

Park, S. I. ;

Lim, M. S. ;

Dittmer, D. P. ;

Damania, B. .

LEUKEMIA, 2010, 24 (10) :1781-1784

[8] A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16 [J].

Billottet, C. ;

Grandage, V. L. ;

Gale, R. E. ;

Quattropani, A. ;

Rommel, C. ;

Vanhaesebroeck, B. ;

Khwaja, A. .

ONCOGENE, 2006, 25 (50) :6648-6659

[9] Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation [J].

Billottet, Clotilde ;

Banerjee, Lalita ;

Vanhaesebroeck, Bart ;

Khwaja, Asim .

CANCER RESEARCH, 2009, 69 (03) :1027-1036

[10]

Borlado LR, 2000, FASEB J, V14, P895

← 1 2 3 4 5 6 →